A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Phase 1 Recruiting
58 enrolled
CERVINO
Phase 3 Recruiting
380 enrolled
MonumenTAL-6
Phase 3 Recruiting
795 enrolled
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1 Recruiting
140 enrolled
SUCCESSOR-1
Phase 3 Recruiting
810 enrolled
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 Recruiting
228 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Phase 1 Recruiting
25 enrolled
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 Recruiting
125 enrolled
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase 3 Recruiting
492 enrolled
MAGNETISMM-5
Phase 3 Recruiting
944 enrolled
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 Recruiting
317 enrolled
ISABELA
Phase 2 Recruiting
50 enrolled
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Recruiting
90 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Phase 2 Recruiting
83 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Phase NA Recruiting
34 enrolled
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Phase 2 Recruiting
43 enrolled
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Phase 2 Recruiting
34 enrolled
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 2 Recruiting
29 enrolled
FUMANBA-03
Phase 3 Recruiting
240 enrolled
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Phase 1/2 Recruiting
53 enrolled
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Phase 1 Recruiting
150 enrolled
KPD Consolidation After ASCT in NDMM Patients
Phase 2/3 Recruiting
202 enrolled
IMPEDE
Phase 2 Recruiting
53 enrolled
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
Phase NA Recruiting
20 enrolled
Daratumumab for Patients With Light Chain Amyloidosis
Phase NA Recruiting
100 enrolled
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
Phase NA Recruiting
35 enrolled